Mechanisms of tumor escape from immune system: Role of mesenchymal stromal cells

Immunology Letters

Volumn 159, Issue 1-2, 2014, Pages 55-72

  Poggi, Alessandro ^a   Musso, Alessandra ^a   Dapino, Irene ^a   Zocchi, Maria Raffaella ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Fibrocytes; Immunosuppression; MSC; NK; NKG2D; TAF

Indexed keywords

ADAM10 ENDOPEPTIDASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL KILLER CELL RECEPTOR NKG2D; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR DECOY RECEPTOR;

ANTIGEN RECOGNITION; BONE MARROW CELL; CD34 SELECTION; CELL ADHESION; CELL INTERACTION; CELL PROLIFERATION; EFFECTOR CELL; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; LYMPHOCYTE; MESENCHYMAL STROMA CELL; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SOLID TUMOR; STEM CELL NICHE; SUPPRESSOR CELL; TUMOR CELL; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; MESENCHYMAL STROMAL CELLS; MYELOID CELLS; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 84897469366     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.03.001     Document Type: Review

References (246)

1. Yang L., Pang Y., Moses H.L. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010, 31:220-227.
2. Yang L. TGFbeta, a potent regulator of tumor microenvironment and host immune response, implication for therapy. Curr Mol Med 2010, 10:374-380.
3. Gajewski T.F., Schreiber H., Fu Y.X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013, 14:1014-1022.
4. Lippitz B.E. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013, 14:e218-e228.
5. Bhatia A., Kumar Y. Cellular and molecular mechanisms in cancer immune escape: a comprehensive review. Expert Rev Clin Immunol 2014, 10:41-62.
6. Li N., Grivennikov S.I., Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 2011, 19:429-431.
7. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22:231-237.
8. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
9. Charbonneau B., Goode E.L., Kalli K.R., Knutson K.L., Derycke M.S. The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol 2013, 33:137-164.
10. Park Y.J., Song B., Kim Y.S., Kim E.K., Lee J.M., Lee G.E., et al. Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells. Cancer Res 2013, 73:5669-5681.
11. Sheu B.C., Chang W.C., Cheng C.Y., Lin H.H., Chang D.Y., Huang S.C. Cytokine regulation networks in the cancer microenvironment. Front Biosci 2008, 13:6255-6268.
12. Kerkar S.P., Restifo N.P. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 2012, 72:3125-3130.
13. Liu Y., Sattarzadeh A., Diepstra A., Visser L., van den Berg A. The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component. Semin Cancer Biol 2013, pii:S1044-579X(13)00064-3.
14. Whiteside T.L., Regulatory T. cell subsets in human cancer: are they regulating for or against tumor progression?. Cancer Immunol Immunother 2014, 63:67-72.
15. Rutkowski M.R., Stephen T.L., Conejo-Garcia J.R. Anti-tumor immunity: myeloid leukocytes control the immune landscape. Cell Immunol 2012, 278:21-26.
16. Hurwitz A.A., Cuss S.M., Stagliano K.E., Zhu Z. T cell avidity and tumor immunity: problems and solutions. Cancer Microenviron 2013, December. [Epub ahead of print].
17. Anandkumar A., Devaraj H. Tumour immunomodulation: mucins in resistance to initiation and maturation of immune response against tumours. Scand J Immunol 2013, 78:1-7.
18. Conti J., Thomas G. The role of tumour stroma in colorectal cancer invasion and metastasis. Cancers (Basel) 2011, 3:2160-2168.
19. Khalili J.S., Liu S., Rodríguez-Cruz T.G., Whittington M., Wardell S., Liu C., et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 2012, 18:5329-5340.
20. Mattoli S., Bellini A., Schmidt M. The role of a human hematopoietic mesenchymal progenitor in wound healing and fibrotic diseases and implications for therapy. Curr Stem Cell Res Ther 2009, 4:266-280.
21. Fenoglio D., Traverso P., Parodi A., Kalli F., Zanetti M., Filaci G. Generation of more effective cancer vaccines. Hum Vaccin Immunother 2013, 9:2543-2547.
22. Eming S.A., Krieg T., Davidson J.M. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol 2007, 127:514-525.
23. Nuschke A. Activity of mesenchymal stem cells in therapies for chronic skin wound healing. Organogenesis 2013, 10(December (1)).
24. Jones B.J., McTaggart S.J. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol 2008, 36:773-841.
25. Kunz-Schughart L.A., Knuechel R. Tumor-associated fibroblasts (part II): functional impact on tumor tissue. Histol Histopathol 2002, 17:623-637.
26. Paraiso K.H., Smalley K.S. Fibroblast-mediated drug resistance in cancer. Biochem Pharmacol 2013, 85:1033-1041.
27. Wood S.L., Pernemalm M., Crosbie P.A., Whetton A.D. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev 2013, pii:S0305-7372(13)00205-3.
28. Esposito M., Kang Y. Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther 2014, 141:222-233.
29. Maccalli C., Volontè A., Cimminiello C., Parmiani G. Immunology of cancer stem cells in solid tumours. A review. Eur J Cancer 2013, pii:S0959-8049(13)01009-5.
30. Kerpedjieva S.S., Kim D.S., Barbeau D.J., Tamama K. EGFR ligands drive multipotential stromal cells to produce multiple growth factors and cytokines via early growth response-1. Stem Cells Dev 2012, 21:2541-2551.
31. Siegel G., Kluba T., Hermanutz-Klein U., Bieback K., Northoff H., Schäfer R. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med 2013, 11:146.
32. Zhang H., Maric I., DiPrima M.J., Khan J., Orentas R.J., Kaplan R.N., et al. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood 2013, 122:1105-1113.
33. van Deventer H.W., Palmieri D.A., Wu Q.P., McCook E.C., Serody J.S. Circulating fibrocytes prepare the lung for cancer metastasis by recruiting Ly-6C+ monocytes via CCL2. J Immunol 2013, 190:4861-4867.
34. Reilkoff R.A., Bucala R., Herzog E.L., Fibrocytes: emerging effector cells in chronic inflammation. Nat Rev Immunol 2011, 11:427-435.
35. Grieb G., Steffens G., Pallua N., Bernhagen J., Bucala R. Circulating fibrocytes - biology and mechanisms in wound healing and scar formation. Int Rev Cell Mol Biol 2011, 291:1-19.
36. Wang C.H., Huang C.D., Lin H.C., Huang T.T., Lee K.Y., Lo Y.L., et al. Increased activation of fibrocytes in patients with chronic obstructive asthma through an epidermal growth factor receptor-dependent pathway. J Allergy Clin Immunol 2012, 129:1367-1376.
37. Galligan C.L., Fish E.N. The role of circulating fibrocytes in inflammation and autoimmunity. J Leukoc Biol 2013, 93:45-50.
38. Stover D.G., Bierie B., Moses H.L. A delicate balance: TGF-beta and the tumor microenvironment. J Cell Biochem 2007, 101:851-856.
39. Calon A., Tauriello D.V., Batlle E. TGF-beta in CAF-mediated tumor growth and metastasis. Semin Cancer Biol 2014, pii:S1044-579X(14)00005-4.
40. Akhurst R.J., Derynck R. TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol 2001, 11:S44-S51.
41. Yang L., Moses H.L. Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer?. Cancer Res 2008, 68:9107-9111.
42. Watanabe T., Wu T.T., Catalano P.J., Ueki T., Satriano R., Haller D.G., et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001, 344:1196-1206.
43. Bruna A., Darken R.S., Rojo F., Ocaña A., Peñuelas S., Arias A., et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 2007, 11:147-160.
44. Arteaga C.L. Inhibition of TGFbeta signaling in cancer therapy. Curr Opin Genet Dev 2006, 16:30-37.
45. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
46. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338.
47. Xie W., Mertens J.C., Reiss D.J., Rimm D.L., Camp R.L., Haffty B.G., et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res 2002, 62:497-505.
48. Pangas S.A., Li X., Umans L., Zwijsen A., Huylebroeck D., Gutierrez C., et al. Conditional deletion of Smad1 and Smad5 in somatic cells of male and female gonads leads to metastatic tumor development in mice. Mol Cell Biol 2008, 28:248-257.
49. Yang G., Li Y., Nishimura E.K., Xin H., Zhou A., Guo Y., et al. Inhibition of PAX3 by TGF-beta modulates melanocyte viability. Mol Cell 2008, 32:554-563.
50. Bierie B., Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006, 6:506-520.
51. Roberts A.B., Wakefield L.M. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003, 100:8621-8623.
52. Gorelik L., Constant S., Flavell R.A. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med 2002, 195:1499-1505.
53. Gorelik L., Flavell R.A. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002, 2:46-53.
54. Li M.O., Flavell R.A. TGF-beta: a master of all T cell trades. Cell 2008, 134:392-404.
55. Li M.O., Wan Y.Y., Sanjabi S., Robertson A.K., Flavell R.A. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006, 24:99-146.
56. Thomas D.A., Massagué J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005, 8:369-380.
57. Trapani J.A. The dual adverse effects of TGF-beta secretion on tumor progression. Cancer Cell 2005, 8:349-350.
58. Fu Z., Zuo Y., Li D., Xu W., Li D., Chen H., et al. The crosstalk: tumor-infiltrating lymphocytes rich in regulatory T cells suppressed cancer-associated fibroblasts. Acta Oncol 2013, 52:1760-1770.
59. Li T., Yang Y., Hua X., Wang G., Liu W., Jia C., et al. Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. Cancer Lett 2012, 318:154-161.
60. Jia C.C., Wang T.T., Liu W., Fu B.S., Hua X., Wang G.Y., et al. Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion. PLoS ONE 2013, 8:e63243.
61. Li T., Yi S., Liu W., Jia C., Wang G., Hua X., et al. Colorectal carcinoma-derived fibroblasts modulate natural killer cell phenotype and antitumor cytotoxicity. Med Oncol 2013, 30:663.
62. Nazareth M.R., Broderick L., Simpson-Abelson M.R., Kelleher R.J., Yokota S.J., Bankert R.B. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol 2007, 178:5552-5562.
63. Phan-Lai V., Florczyk S.J., Kievit F.M., Wang K., Gad E., Disis M.L., et al. Three-dimensional scaffolds to evaluate tumor associated fibroblast-mediated suppression of breast tumor specific T cells. Biomacromolecules 2013, 14:1330-1337.
64. Liao D., Luo Y., Markowitz D., Xiang R., Reisfeld R.A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE 2009, 4:e7965.
65. Balsamo M., Scordamaglia F., Pietra G., Manzini C., Cantoni C., Boitano M., et al. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci USA 2009, 106:20847-20852.
66. Wen Y., Wang C.T., Ma T.T., Li Z.Y., Zhou L.N., Mu B., et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci 2010, 101:2325-2332.
67. Pinchuk I.V., Saada J.I., Beswick E.J., Boya G., Qiu S.M., Mifflin R.C., et al. PD-1 ligand expression by human colonic myofibroblasts/fibroblasts regulates CD4+ T-cell activity. Gastroenterology 2008, 135:1228-1237.
68. Bianchi G., Borgonovo G., Pistoia V., Raffaghello L. Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells. Histol Histopathol 2011, 26:941-951.
69. Pradier A., Passweg J., Villard J., Kindler V. Human bone marrow stromal cells and skin fibroblasts inhibit natural killer cell proliferation and cytotoxic activity. Cell Transplant 2011, 20:681-691.
70. Barnas J.L., Simpson-Abelson M.R., Yokota S.J., Kelleher R.J., Bankert R.B. T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets. Cancer Microenviron 2010, 3:29-47.
71. Kakarla S., Chow KKh, Mata M., Shaffer D.R., Song X.T., Wu M.F., et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther 2013, 21:1611-1620.
72. Togo S., Polanska U.M., Horimoto Y., Orimo A. Carcinoma-associated fibroblasts are a promising therapeutic target. Cancers 2013, 5:149-169.
73. Kraman M., Bambrough P.J., Arnold J.N., Roberts E.W., Magiera L., Jones J.O., et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010, 330:827-830.
74. Zhu L., Cheng X., Ding Y., Shi J., Jin H., Wang H., et al. Bone marrow-derived myofibroblasts promote colon tumorigenesis through the IL-6/JAK2/STAT3 pathway. Cancer Lett 2014, 343:80-89.
75. Haniffa M.A., Wang X.N., Holtick U., Rae M., Isaacs J.D., Dickinson A.M., et al. Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol 2007, 179:1595-1604.
76. Schmieder A., Michel J., Schönhaar K., Goerdt S., Schledzewski K. Differentiation and gene expression profile of tumor-associated macrophages. Semin Cancer Biol 2012, 22:289-297.
77. Stagg J., Smyth M.J. Extarcellular adenosine triphosphate and adenosine in cancer. Oncogene 2010, 29:5356-5358.
78. Zitvogel L., Kepp O., Galluzzi L., Kromer G. Inflammasomes in carcinogenesis and anticancer immune response. Nat Immunol 2012, 13:343-351.
79. Fredholm B.B., IJzerman A.P., Jacobson K.A., Linden J., Müller C.E. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors -an update. Pharmacol Rev 2011, 63:1-34.
80. Serra S., Horenstein A.L., Vaisitti T., Brusa D., Rossi D., Laurenti L., et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 2011, 118:6141-6152.
81. Bavaresco L., Bernardi A., Braganhol E., Cappellari A.R., Rockenbach L., Farias P.F., et al. The role of ecto-5'-nucleotidase/CD73 in glioma cell line proliferation. Mol Cell Biochem 2008, 319:61-68.
82. Sadej R., Skladanowski A.C. Dual, enzymatic and non-enzymatic, function of ecto-5'-nucleotidase (eN, CD73) in migration and invasion of A375 melanoma cells. Acta Biochim Pol 2012, 59:647-652.
83. Sadej R., Spychala J., Skladanowski A.C. Expression of ecto-5'-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res 2006, 16:213-222.
84. Deaglio S., Dwyer K.M., Gao W., Friedman D., Usheva A., Erat A., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007, 204:1257-1265.
85. Regateiro F.S., Howie D., Nolan K.F., Agorogiannis E.I., Greaves D.R., Cobbold S.P., et al. Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-β. Eur J Immunol 2011, 41:2955-2965.
86. Borsellino G., Kleinewietfeld M., Di Mitri D., Sternjak A., Diamantini A., Giometto R., et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007, 110:1225-1233.
87. Ålgars A., Karikoski M., Yegutkin G.G., Stoitzner P., Niemelä J., Salmi M., et al. Different role of CD73 in leukocyte trafficking via blood and lymph vessels. Blood 2011, 117:4387-4393.
88. Algars A., Irjala H., Vaittinen S., Huhtinen H., Sundström J., Salmi M., et al. Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. Int J Cancer 2012, 131:864-873.
89. Allard B., Turcotte M., Stagg J. CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol 2012, 2012:485156.
90. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
91. Djouad F., Plence P., Bony C., Tropel P., Apparailly F., Sany J., et al. Immunosuppressive effect of mesenchymal stem cells favors tumour growth in allogeneic animals. Blood 2003, 102:3837-3844.
92. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
93. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110:3499-3506.
94. Mougiakakos D., Jitschin R., Johansson C.C., Okita R., Kiessling R., Le Blanc K. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 2011, 117:4826-4835.
95. Soleymaninejadian E., Pramanik K., Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol 2012, 67:1-8.
96. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., et al. Evidence for a tumoural immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003, 9:1269-1274.
97. Vig M., Srivastava S., Kandpal U., Sade H., Lewis V., Sarin A., et al. Inducible oxid nitric synthase in T cells regulates T cell death and immune memory. J Clin Invest 2004, 113:1734-1742.
98. Von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005, 6:338-343.
99. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting from immunosurveillance to tumour escape. Nat Immunol 2002, 3:991-998.
100. Prendergast G.C., Chang M.Y., Mandik-Nayak L., Metz R., Muller A.J. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem 2011, 18:2257-2262.
101. Ino Y., Yamazaki-Itoh R., Oguro S., Shimada K., Kosuge T., Zavada J., et al. Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS ONE 2013, 8:e55146.
102. Barnas J.L., Simpson-Abelson M.R., Brooks S.P., Kelleher R.J., Bankert R.B. Reciprocal functional modulation of the activation of T lymphocytes and fibroblasts derived from human solid tumors. J Immunol 2010, 185:2681-2692.
103. Catteau X., Simon P., Vanhaeverbeek M., Noël J.C. Variable stromal periductular expression of CD34 and smooth muscle actin (SMA) in intraductal carcinoma of the breast. PLoS One 2013, 8:e57773.
104. Direkze N.C., Hodivala-Dilke K., Jeffery R., Hunt T., Poulsom R., Oukrif D., et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res 2004, 64:8492-8495.
105. Carothers A.M., Rizvi H., Hasson R.M., Heit Y.I., Davids J.S., Bertagnolli M.M., et al. Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors. Cancer Res 2012, 72:346-355.
106. Ferrero E., Bondanza A., Leone B.E., Manici S., Poggi A., Zocchi M.R. CD14+ CD34+ peripheral blood mononuclear cells migrate across endothelium and give rise to immunostimulatory dendritic cells. J Immunol 1998, 160:2675-2683.
107. Ferrero E., Belloni D., Contini P., Foglieni C., Ferrero M.E., Fabbri M., et al. Transendothelial migration leads to protection from starvation-induced apoptosis in CD34+CD14+ circulating precursors: evidence for PECAM-1 involvement through Akt/PKB activation. Blood 2003, 101:186-193.
108. Steidl C., Connors J.M., Gascoyne R.D. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011, 29:1-15.
109. Montes-Moreno S. Hodgkin's Lymphomas: a tumor recognized by its microenvironment. Adv Hematol 2011, 2011:142395.
110. Carbone A., Gloghini A., Cabras A., Elia G. The Germinal centre-derived lymphomas seen through their cellular microenvironment. Br J Haematol 2009, 145:468-480.
111. Kuppers R., Engert A., Hausmann M.L. Hodgkin lymphoma. J Clin Invest 2012, 122:3439-3447.
112. Mourcin F., Pangault C., Amin-Ali R., Amé-Thomas P., Tarte K. Stromal cell contribution to human follicular lymphoma pathogenesis. Front Immunol 2012, 3:280.
113. Burger J.A., Ford R.J. The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies. Semin Cancer Biol 2011, 21:308-312.
114. Kridel R., Sehn L.H., Gascoyne R.D.J. Pathogenesis of follicular lymphoma. Clin Invest 2012, 122:3424-3431.
115. Zocchi M.R., Catellani S., Canevali P., Tavella S., Garuti A., Villaggio B., et al. High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D-ligands recognition in Hodgkin lymphomas. Blood 2012, 119:1479-1489.
116. Musso A., Catellani S., Canevali P., Tavella S., Venè R., Boero S., et al. Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2T lymphocytes in non-Hodgkin lymphomas. Haematologica 2014, 99:131-139.
117. Skinnider B.F., Mak T.W. The role of cytokines in classical Hodgkin lymphoma. Blood 2002, 99:4283-4342.
118. Wang Z., Yan X. CD146, a multi-functional molecule beyond adhesion. Cancer Lett 2013, 330:150-162.
119. Poggi A., Zocchi M.R. NK cell autoreactivity and autoimmune diseases. Front Immunol 2014, In the press.
120. Bottino C., Castriconi R., Pende D., Rivera P., Nanni M., Carnemolla B., et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003, 198:557-567.
121. Zingoni A., Ardolino M., Santoni A., Cerboni C. NKG2D and DNAM-1 activating receptors and their lignads in NK-T interactions: role in NK cell-mediated negative regulation of T cell responses. Front Immunol 2013, 3:408.
122. Kaiser B.K., Yim D., Chow I.-T., Gonzales S., Dai Z., Mann H.H., et al. Disulphide-isomerase-enabled shedding of tumor-associated NKG2D ligands. Nature 2007, 447:482-487.
123. Waldhauer I., Goehlsdorf D., Gieseke F., Weinschenk T., Wittenbrink M., Ludwig A., et al. Tumor-associated MICA is shed by ADAM proteases. Cancer Res 2008, 68:6368-6376.
124. Kohga K., Takehara T., Tatsumi T., Miyagi T., Ishida H., Ohkawa K., et al. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Cancer Res 2009, 69:8050-8057.
125. Ribatti D., Basile A., Ruggieri S., Vacca A. Bone marrow vascular niche and the control of angiogenesis in multiple myeloma. Front Biosci (Landmark Ed) 2014, 19:304-311.
126. Anthony B.A., Link D.C. regulation of hematopoietic stem cells by bone marrow stromal cells. Trends Immunol 2014, 35:32-37.
127. Roozen P.P., Brugman M.H., Staal F.J. Differential requirements for Wnt and Notch signaling in hematopoietic versus thymic niches. Ann N Y Acad Sci 2012, 1266:78-93.
128. Chitteti B.R., Cheng Y.H., Poteat B., Rodriguez-Rodriguez S., Goebel W.S., Carlesso N., et al. Impact of interactions of cellular components of the bone marrow microenvironment on hematopoietic stem and progenitor cell function. Blood 2010, 115:3239-3248.
129. Yamazaki S., Iwama A., Takayanagi S., Eto K., Ema H., Nakauchi H. TGF-beta as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood 2009, 113:1250-1256.
130. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107:367-372.
131. Traggiai E., Volpi S., Schena F., Gattorno M., Ferlito F., Moretta L., et al. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 2008, 26:562-569.
132. Franquesa M., Hoogduijn M.J., Bestard O., Grinyó J.M. Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol 2012, 3:212.
133. Meisel R., Zibert A., Laryea M., Göbel U., Däubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
134. Najar M., Rouas R., Raicevic G., Boufker H.I., Lewalle P., Meuleman N., et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 2009, 11:570-583.
135. Musso A., Zocchi M.R., Poggi A. Relevance of the mevalonate biosynthetic pathway in the regulation of bone marrow mesenchymal stromal cell-mediated effects on T-cell proliferation and B-cell survival. Haematologica 2011, 96:16-23.
136. Prevosto C., Zancolli M., Canevali P., Zocchi M.R., Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 2007, 92:881-888.
137. Maccario R., Podestà M., Moretta A., Cometa A., Comoli P., Montagna D., et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005, 90:516-525.
138. Balermpas P., Michel Y., Wagenblast J., Seitz O., Weiss C., Rödel F., et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer 2014, 110:501-509.
139. Laghi L., Bianchi P., Miranda E., Balladore E., Pacetti V., Grizzi F., et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 2009, 10:877-884.
140. Ruffini E., Asioli S., Filosso P.L., Lyberis P., Bruna M.C., Macrì L., et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg 2009, 87:365-371.
141. Zhong H., Gutkin D.W., Han B., Ma Y., Keskinov A.A., Shurin M.R., et al. Origin and pharmacological modulation of tumor-associated regulatory dendritic cells. Int J Cancer 2013, November.
142. Driessens G., Kline J., Gajewski T.F. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev 2009, 229:126-144.
143. Gallois A., Bhardwaj N. Dendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironment. Front Immunol 2013 Dec 10, 4:436.
144. Seliger B., Quandt D. The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother 2012, 61:1327-1341.
145. Krambeck A.E., Thompson R.H., Dong H., Lohse C.M., Park E.S., Kuntz S.M., et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA 2006, 103:10391-10396.
146. Sica G.L., Choi I.H., Zhu G., Tamada K., Wang S.D., Tamura H., et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003, 18:849-861.
147. Salceda S., Tang T., Kmet M., Munteanu A., Ghosh M., Macina R., et al. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res 2005, 306:128-141.
148. Gratz I.K., Rosenblum M.D., Maurano M.M., Paw J.S., Truong H.A., Marshak-Rothstein A., et al. Cutting edge: self-antigen controls the balance between effector and regulatory T cells in peripheral tissues. J Immunol 2014, January.
149. Wang M., Tian T., Yu S., He N., Ma D. Th17 and Treg cells in bone related diseases. Clin Dev Immunol 2013, 2013:203705.
150. Pagès F. Tumor-associated immune parameters for personalized patient care. Sci Transl Med 2013, 5(214):214fs42.
151. Bindea G., Mlecnik B., Tosolini M., Kirilovsky A., Waldner M., Obenauf A.C., et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013, 39:782-795.
152. Azimi F., Scolyer R.A., Rumcheva P., Moncrieff M., Murali R., McCarthy S.W., et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 2012, 30:2678-2683.
153. Kreike B., van Kouwenhove M., Horlings H., Weigelt B., Peterse H., Bartelink H., et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007, 9:R65.
154. Mahmoud S.M., Lee A.H., Paish E.C., Macmillan R.D., Ellis I.O., Green A.R. Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol 2012, 65:159-163.
155. Liu H., Zhang T., Ye J., Li H., Huang J., Li X., et al. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother 2012, 61:1849-1856.
156. Rusakiewicz S., Semeraro M., Sarabi M., Desbois M., Locher C., Mendez R., et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 2013, 73:3499-3510.
157. Curiel T.J., Wei S., Dong H., Alvarez X., Cheng P., Mottram P., et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003, 9:562-567.
158. Wolf D., Wolf A.M., Rumpold H., Fiegl H., Zeimet A.G., Muller-Holzner E., et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005, 11:8326-8331.
159. Benevides L., Cardoso C.R., Tiezzi D.G., Marana H.R., Andrade J.M., Silva J.S. Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur J Immunol 2013, 43:1518-1528.
160. Grosso J.F., Jure-Kunkel M.N. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013, 13:5.
161. Macatangay B.J., Rinaldo C.R. PD-1 blockade: a promising immunotherapy for HIV?. Cell Science 2009, 5:61-65.
162. Maus M.V., Fraietta J.A., Levine B.L., Kalos M., Zhao Y., June C.H. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 2014, January.
163. Nasser R., Pelegrin M., Plays M., Gros L., Piechaczyk M. Control of regulatory T cells is necessary for vaccine-like effects of antiviral immunotherapy by monoclonal antibodies. Blood 2013, 121:1102-1111.
164. Bonneville M., O'Brien R.L., Born W.K., Gammadelta T. cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010, 10:467-478.
165. Butt A.Q., Mills K.H. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene 2013, October.
166. Elinav E., Nowarski R., Thaiss C.A., Hu B., Jin C., Flavell R.A. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2013, 13:759-771.
167. Liao W., Lin J.X., Leonard W.J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013, 38:13-25.
168. Galandrini R., Capuano C., Santoni A. Activation of lymphocyte cytolytic machinery: where are we?. Front Immunol 2013, 4:390.
169. Poggi A., Zocchi M.R. Human natural killer lymphocytes through the engagement of natural cytotoxicity receptors and NKG2D can trigger self-aggression. Autoimmun Rev 2007, 6:295-299.
170. Nausch N. A Cerwenka. NKG2D ligands in tumor immunity. Oncogene 2008, 27:5944-5958.
171. Poggi A., Venturino C., Catellani S., Clavio M., Miglino M., Gobbi M., et al. Vdelta1T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res 2004, 64:9172-9179.
172. Lee J.C., Lee K.M., Kim D.W., Heo D.S. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004, 172:7335-7340.
173. Champsaur M., Lanier L.L. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010, 235:267-285.
174. Diermayr S., Himmelreich H., Durovic B., Mathys-Scheeberger A., Siegler U., Langenkamp U., et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008, 111:1428-1436.
175. Poggi A., Catellani S., Garuti A., Pierri I., Gobbi M., Zocchi M.R. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 2009, 23:641-648.
176. Hayday A.C., Gammadelta T. cells and the lymphoid stress-surveillance response. Immunity 2009, 31:184-196.
177. Vivier E., Raulet D.H., Moretta A., Caligiuri M.A., Zitvogel L., Lanier L.L., et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
178. Waggoner S.N., Kumar V. Evolving role of 2B4/CD244 in T and NK cell responses during virus infection. Front Immunol 2012, 3:377.
179. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19:197-223.
180. Lanier L.L. NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
181. Poggi A., Tomasello E., Ferrero E., Zocchi M.R., Moretta L. p40/LAIR-1 regulates the differentiation of peripheral blood precursors to dendritic cells induced by granulocyte-monocyte colony-stimulating factor. Eur J Immunol 1999, 28:2086-2091.
182. Meyaard L. The inhibitory collagen receptor LAIR-1 (CD305). J Leukoc Biol 2008, 83:799-803.
183. Vasu S., Caligiuri M.A. Targeted immunotherapy for acute myeloid leukemia. Best Pract Res Clin Haematol 2011, 24:533-540.
184. Allavena P., Sica A., Garlanda C., Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008, 222:155-161.
185. Baginska J., Viry E., Paggetti J., Medves S., Berchem G., Moussay E., et al. The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol 2013 Dec 25, 4:490.
186. Wolchok J.D., Hodi F.S., Weber J.S., Allison J.P., Urba W.J., Robert C., et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013, 1291:1-13.
187. Kline J., Gajewski T.F. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs 2010, 11:1354-1359.
188. Gray-Owen S.D., Blumberg R.S. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol 2006, 6:433-446.
189. Hodi F.S. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2007, 13:5238-5242.
190. Quandt D., Fiedler E., Boettcher D., Marsch WCh, Seliger B. B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin Cancer Res 2011, 17:3100-3111.
191. Karakatsanis S., Bertsias G., Roussou P., Boumpas D. Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant T-lymphoproliferative disorders: brief review. Hematol Oncol 2013, September.
192. Merelli B., Massi D., Cattaneo L., Mandalà M. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol 2014, 89:140-165.
193. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
194. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
195. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010, 107:4275-4280.
196. Papkoff J. New solid tumor targets for therapeutic monoclonal antibodies. Expert Opin Ther Targets 2007, 11:585-588.
197. Krambeck A.E., Dong H., Thompson R.H., Kuntz S.M., Lohse C.M., Leibovich B.C., et al. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res 2007, 13:1749-1756.
198. Jiang J., Zhu Y., Wu C., Shen Y., Wei W., Chen L., et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother 2010, 59:1707-1714.
199. Kuespert K., Pils S., Hauck C.R. CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol 2006, 18:565-571.
200. Markel G., Wolf D., Hanna J., Gazit R., Goldman-Wohl D., Lavy Y., et al. Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest 2002, 110:943-953.
201. Chen W.J., Chen H.W., Yu S.L., Huang C.H., Wang T.D., Chen J.J., et al. Gene expression profiles in hypoxic preconditioning using cDNA microarray analysis: altered expression of an angiogenic factor, carcinoembryonic antigen-related cell adhesion molecule 1. Shock 2005, 24:124-131.
202. Nagaishi T., Iijima H., Nakajima A., Chen D., Blumberg R.S. Role of CEACAM1 as a regulator of T cells. Ann N Y Acad Sci 2006, 1072:155-175.
203. Ortenberg R., Sapir Y., Raz L., Hershkovitz L., Ben Arav A., et al. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions. Mol Cancer Ther 2012, 11:1300-1310.
204. Nagaishi T., Pao L., Lin S.H., Iijima H., Kaser A., Qiao S.W., et al. SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity 2006, 25:769-781.
205. Markel G., Gruda R., Achdout H., Katz G., Nechama M., Blumberg R.S., et al. The critical role of residues 43R and 44Q of carcinoembryonic antigen cell adhesion molecules-1 in the protection from killing by human NK cells. J Immunol 2004, 173:3732-3739.
206. Ebrahimnejad A., Streichert T., Nollau P., Horst A.K., Wagener C., Bamberger A.M., et al. CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. Am J Pathol 2004, 165:1781-1787.
207. Thies A., Mauer S., Fodstad O., Schumacher U. Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice. Br J Cancer 2007, 96:609-616.
208. Lebbink R.J., de Ruiter T., Adelmeijer J., Brenkman A.B., van Helvoort J.M., Koch M., et al. Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. J Exp Med 2006, 203:1419-1425.
209. Lebbink R.J., Raynal N., de Ruiter T., Bihan D.G., Farndale R.W., Meyaard L. Identification of multiple potent binding sites for human leukocyte associated Ig-like receptor LAIR on collagens II and III. Matrix Biol 2009, 28:202-210.
210. Poggi A., Tomasello E., Revello V., Nanni L., Costa P., Moretta L. p40 molecule regulates NK cell activation mediated by NK receptors for HLA class I antigens and TCR-mediated triggering of T lymphocytes. Int Immunol 1997, 9:1271-1279.
211. Poggi A., Pella N., Morelli L., Spada F., Revello V., Sivori S., et al. p40, a novel surface molecule involved in the regulation of the non-major histocompatibility complex-restricted cytolytic activity in humans. Eur J Immunol 1995, 25:369-376.
212. Meyaard L., Hurenkamp J., Clevers H., Lanier L.L., Phillips J.H. Leukocyte associated Ig-like receptor-1 functions as an inhibitory receptor on cytotoxic T cells. J Immunol 1999, 162:5800-5804.
213. Colombo B.M., Canevali P., Magnani O., Rossi E., Puppo F., Zocchi M.R., et al. Defective expression and function of the leukocyte associated Ig-like receptor 1 in B lymphocytes from sistemi lupus erythematosus patients. PLoS ONE 2012, 7:e31903.
214. Poggi A., Catellani S., Bruzzone A., Caligaris-Cappio F., Gobbi M., Zocchi M.R. Lack of the leukocyte-associated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division. Leukemia 2008, 22:980-988.
215. Poggi A., Pellegatta F., Leone B.E., Moretta L., Zocchi M.R. Engagement of the leukocyteassociated Ig-like receptor-1 induces programmed cell death and prevents NF-kappaB nuclear translocation in human myeloid leukemias. Eur J Immunol 2000, 30:2751-2758.
216. Merlo A., Tenca C., Fais F., Battini L., Ciccone E., Grossi C.E., et al. Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes. Clin Diagn Lab Immunol 2005, 12:705-712.
217. van der Vuurst de Vries A.R., Clevers H., Logtenberg T., Meyaard L. Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is differentially expressed during human B cell differentiation and inhibits B cell receptor mediated signaling. Eur J Immunol 1999, 29:3160-3167.
218. Schoppmann S.F., Berghoff A., Dinhof C., Jakesz R., Gnant M., Dubsky P., et al. Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Res Treat 2012, 134:237-244.
219. Edlund K., Lindskog C., Saito A., Berglund A., Pontén F., Göransson-Kultima H., et al. CD99 is a novel prognostic stromal marker in non-small cell lung cancer. Int J Cancer 2012, 131:2264-2273.
220. Boudjadi S., Carrier J.C., Beaulieu J.F. Integrin α1 subunit is up-regulated in colorectal cancer. Biomark Res 2013, 1:16.
221. Jinushi M., Vanneman M., Munshi N.C., Tai Y.T., Prabhala R.H., Ritz J., et al. MIC-A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA 2008, 105:1285-1290.
222. Nückel H., Switala M., Sellmann L., Horn P.A., Dürig J., Dührsen U., et al. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 2010, 24:1152-1159.
223. Shurin M.R., Shurin G.V., Lokshin A., Yurkovetsky Z.R., Gutkin D.W., Chatta G., et al. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?. Cancer Metastasis Rev 2006, 25:333-356.
224. Golubovskaya V.M., Targeting F.A.K. in human cancer: from finding to first clinical trials. Front Biosci (Landmark Ed). 2014, 19:687-706.
225. Johansson J., Berg T., Kurzejamska E., Pang M.F., Tabor V., Jansson M., et al. MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene 2013, 32:5614-5624.
226. Mundy G.R., Yoneda T., Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol 2001, 28(2 Suppl. 6):35-44.
227. van de Donk N.W., Görgün G., Groen R.W., Jakubikova J., Mitsiades C.S., Hideshima T., et al. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res 2012, 4:253-268.
228. Laubach J.P., Schlossman R.L., Mitsiades C.S., Anderson K.C., Richardson P.G. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Rev Hematol 2011, 4:51-60.
229. Laubach J., Richardson P., Anderson K. Multiple myeloma. Annu Rev Med 2011, 62:249-264.
230. Kümler I., Tuxen M.K., Nielsen D.L. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev 2014, 40:259-270.
231. Kennecke H., Chen L., Blanke C.D., Cheung W.Y., Schaff K., Speers C. Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer. Curr Oncol 2013, 20:326-332.
232. Benelli R., Venè R., Minghelli S., Carlone S., Gatteschi B., Ferrari N. Celecoxib induces proliferation and Amphiregulin production in colon subepithelial myofibroblasts, activating erk1-2 signaling in synergy with EGFR. Cancer Lett 2013, 328:73-82.
233. Fekete N., Rojewski M.T., Lotfi R., Schrezenmeier H. Essential components for ex vivo proliferation of mesenchymal stromal cells. Tissue Eng Part C Methods 2013, July.
234. Beiggi S., Johnston J.B., Seftel M.D., Pitz M.W., Kumar R., Banerji V., et al. Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study. Br J Cancer 2013, 109:1287-1290.
235. Chu-Yuan H., Jing P., Yi-Sheng W., He-Ping P., Hui Y., Chu-Xiong Z., et al. The impact of chemotherapy-associated neutrophil/lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer. BMC Cancer 2013, 13:177.
236. Kanagal-Shamanna R., Yin C.C., Miranda R.N., Bueso-Ramos C.E., Wang X.I., Muddasani R., et al. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q). Cancer Genet 2013, 206:42-46.
237. Vansteenkiste J., Wauters I., Elliott S., Glaspy J., Hedenus M. Chemotherapy-induced anemia: the story of darbepoetin alfa. Curr Med Res Opin 2013, 29:325-337.
238. Davies C., Pan H., Godwin J., Gray R., Arriagada R., Raina V., et al. Adjuvant Tamoxifen: Longer Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, Against Shorter (ATLAS) Collaborative Group. Lancet 2013, 381:805-816. Erratum in: Lancet 2013;381(9869):804.
239. Chim C.S., Choi P.T., Lee W.K. Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide. Ann Hematol 2013, 92:855-857.
240. Raissouni S., Raissouni F., Rais G., Aitelhaj M., Lkhoyaali S., Latib R., et al. Radiation induced esophageal adenocarcinoma in a woman previously treated for breast cancer and renal cell carcinoma. BMC Res Notes 2012, 5:426.
241. Dimarino A.M., Caplan A.I., Bonfield T.L. Mesenchymal stem cells in tissue repair. Front Immunol 2013, 4:201. eCollection 2013.
242. Harper J., Sainson R.C. regulation of the anti-tumour immune response by cancer associated fibroblasts. Semin Cancer Biol 2014, January. pii:S1044-579X(14)00002-9.
243. Spits H., Di Santo J.P. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011, 12:21-27.
244. Poggi A., Carosio R., Spaggiari G.M., Fortis C., Tambussi G., Dell'Antonio G., et al. NK cell activation by dendritic cells is dependent on LFA-1-mediated induction of calcium-calmodulin kinase II: inhibition by HIV-1 Tat C-terminal domain. J Immunol 2002, 168:95-101.
245. Poggi A., Zocchi M.R., Carosio R., Ferrero E., Angelini D.F., Galgani S., et al. transendothelial migratory pathways on Vδ1+ TCRγδ+ and Vδ2+ TCRγδ+ T lymphocytes from healthy donors and multiple sclerosis patients: involvement of phosphatidylicositol 3 kinase and calcium calmoduli-dependent kinase II. J Immunol 2002, 168:6071-6077.
246. Poggi A., Boero S., Musso A., Zocchi M.R. Selective role of mevalonate pathway in regulating perforin but not FasL and TNFalpha release in human natural killer cells. PLos ONE 2013, 8:e62932.